Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

SUNNYVALE, Calif. , Sept. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Seth Blacksburg, M.D.

Dr. Seth Blacksburg Joins Accuray as VP, Chief Medical Officer Americas Region

Accuray (ARAY) partners with Genolier Innovation Hub to unite companies from the MedTech, pharma and biosciences sectors with physicians and scientists for better patient outcomes.

Accuray's (ARAY) Latest Collaboration to Improve Patient Care

Accuray Will Anchor Hub That Will Unite Companies From the MedTech, Pharma and Biosciences Sectors, Physicians and Scientists SUNNYVALE, Calif. , Sept. 7, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA (SWX: AEVS), in support of a unique new approach to improving patient care.

Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster

Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.

Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down

Accuray Incorporated (NASDAQ:ARAY ) Q4 2022 Results Conference Call August 10, 2022 4:30 PM ET Company Participants Ken Mobeck - Vice President-Finance Suzanne Winter - President & Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Neil Chatterji - B. Riley Marie Thibault - BTIG Josh Jennings - Cowen Jason Wittes - Loop Capital Operator Good afternoon, and welcome to the Accuray Fourth Quarter 2022 Financial Results Conference Call.

Accuray Incorporated (ARAY) CEO Suzanne Winter on Q4 2022 Results - Earnings Call Transcript

Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 4.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates

8.5% FY22 revenue growth; Company issues guidance for FY23 SUNNYVALE, Calif. , Aug. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2022 ended June 30, 2022.

Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results

SUNNYVALE, Calif. , July 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2022, ended June 30, 2022, after the market close on August 10, 2022.

Accuray to Report Fiscal Year-End 2022 Financial Results on August 10, 2022

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now

SUNNYVALE, Calif. , July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife® platform in the treatment of neurological indications with non-invasive radiosurgery.

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications

SUNNYVALE, Calif. , June 15, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Franco N.

Accuray Appoints Franco N. Palomba as VP, Chief Accounting Officer & Controller

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

SUNNYVALE, Calif. , June 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Sandeep Chalke, the company's new senior vice president, chief commercial officer.

Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules

Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.

Accuray's (ARAY) New Tie-Up to Augment Treatment Planning

Partnership will Enable Accuray to Use Limbus' Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency SUNNYVALE, Calif. and SASKATCHEWAN, Canada , June 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc. announced today they are partnering to augment Accuray adaptive radiotherapy capabilities by leveraging Limbus' artificial intelligence (AI)-driven autocontouring algorithms - enabling automated contouring to further streamline the treatment planning process*.

Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions

SUNNYVALE, Calif. , May 17, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Sandeep Chalke has joined the company as senior vice president, chief commercial officer effective May 16, 2022.

Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer

More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies SUNNYVALE, Calif. , May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife® and TomoTherapy® platforms, including the next-generation Radixact® System, to accurately and efficiently treat a wide variety of indications of all complexities.

New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities

Accuray (ARAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 20% in 4 Weeks, Here's Why Accuray (ARAY) Looks Ripe for a Turnaround

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies SUNNYVALE, Calif. , May 5, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its ClearRT™ helical fan-beam kVCT imaging capability for the Radixact® System has been selected as the winner of the "Best New Technology Solution for Oncology" award in the sixth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough.

Accuray ClearRT™ Helical Fan-Beam kVCT Imaging Wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award

Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.

Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag

Accuray Incorporated (NASDAQ:ARAY ) Q3 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Ken Mobeck – Vice President-Finance Josh Levine – Chief Executive Officer Suzanne Winter – President Brandy Green – Interim Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Marie Thibault – BTIG Josh Jennings – Cowen Frank Pinal – Jefferies Jason Wittes – Loop Capital Operator Good afternoon, and welcome to the Accuray Third Quarter Fiscal 2022 Financial Results Conference Call. [Operator instructions] Please note this event is being recorded.

Accuray's (ARAY) CEO Josh Levine on Q3 2022 Results - Earnings Call Transcript

Accuray (ARAY) delivered earnings and revenue surprises of 83.33% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Q3 Loss, Misses Revenue Estimates

SUNNYVALE, Calif. , April 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter of fiscal 2022 ended March 31, 2022.

Accuray Reports Fiscal 2022 Third Quarter Financial Results

Accuray Also Announces Chief Financial Officer, Ali Pervaiz SUNNYVALE, Calif. , April 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Suzanne Winter, President, will succeed Joshua Levine as the company's Chief Executive Officer, effective July 1, 2022.

Accuray Announces Suzanne Winter, President, Promoted to President and CEO; Joshua Levine Will Retire as CEO and Board Member

SUNNYVALE, Calif. , April 21, 2022 /PRNewswire/ -- When Al Gold, the owner of the Arkansas Derby winner Cyberknife, received a diagnosis of prostate cancer, he was determined to find a potential cure for his disease while minimizing the impact of treatment on his daily life.

News for Accuray Stock (ARAY)